GlassScriptPhysician profile
Jordan Reiche
NPI 1649847617
$712.05
in general payments reported to CMS, 2019-2025
17 companies · $171 in 2025
The $171 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $28.32 · 2024: $513 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $712.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $100.96 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $74.29 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $66.15 | 2024-2025 | Spravato |
| Noven Therapeutics, LLC | $65.82 | 2024 | Xelstrym |
| Vanda Pharmaceuticals INC. | $59.36 | 2024 | Hetlioz, Fanapt |
| Tempus Ai, INC | $56.13 | 2024 | |
| Abbvie INC. | $49.68 | 2024-2025 | |
| Indivior INC. | $36.52 | 2024 | Sublocade |
| Teva Pharmaceuticals USA, INC. | $35.14 | 2024 | Austedo Xr |
| Almatica Pharma LLC | $28.67 | 2024 | Loreev Xr, Teriparatide |
| Neurocrine Biosciences, INC. | $28.32 | 2023 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $22.54 | 2025 | Qelbree |
| Alkermes, INC. | $21.23 | 2025 | Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.55 | 2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $18.31 | 2024 | Quviviq |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tms Neurohealth Centers INC. | $16.21 | 2025 | Tms Neurohealth Centers INC. |
| Neos Therapeutics, LP | $13.17 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Reiche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.